Who are Duobrii 0.01 % / 0.045 % Topical Lotion's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/duobrii-0-01-0-045-topical-lotion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Duobrii 0.01 % / 0.045 % Topical Lotion — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duobrii 0.01 % / 0.045 % Topical Lotion (Duobrii 0.01 % / 0.045 % Topical Lotion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical corticosteroid + retinoid combination. Area: Dermatology.

phase 3 Topical corticosteroid + retinoid combination Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Duobrii 0.01 % / 0.045 % Topical Lotion (Duobrii 0.01 % / 0.045 % Topical Lotion) — Austin Institute for Clinical Research. Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duobrii 0.01 % / 0.045 % Topical Lotion TARGET	Duobrii 0.01 % / 0.045 % Topical Lotion	Austin Institute for Clinical Research	phase 3	Topical corticosteroid + retinoid combination	Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical corticosteroid + retinoid combination class)

Austin Institute for Clinical Research · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duobrii 0.01 % / 0.045 % Topical Lotion — Competitive Intelligence Brief. https://druglandscape.com/ci/duobrii-0-01-0-045-topical-lotion. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab